MARKET

DTCFF

DTCFF

Defence Therapeu
OTCMQB
0.460
NaN%
Opening 09:30 02/10 EST
OPEN
--
PREV CLOSE
0.435
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
1.150
52 WEEK LOW
0.386
MARKET CAP
26.37M
P/E (TTM)
-9.0551
1D
5D
1M
3M
1Y
5Y
1D
Defence Therapeutics Refines Accum ADC Strategy with Expert Advisory Board
TipRanks · 7h ago
Defence Therapeutics Refines Accum ADC Strategy With New Scientific Advisory Board
TipRanks · 7h ago
Defence Therapeutics plant die Weiterentwicklung und strategische Ausrichtung der Accum ADC-Plattform für klinische Anwendungen und Partnerschaften
Reuters · 12h ago
Defence Therapeutics Inc. Refines Accum ADC Development Roadmap to Align Platform Capabilities with Clinical Requirements and Partnering Opportunities, Aiming for More Effective Intracellular Delivery Solutions
Reuters · 12h ago
Defence Therapeutics Aligns Accum ADC Strategy Through Multidisciplinary Scientific Advisory Board
Newsfile · 12h ago
Weekly Report: what happened at DTCFF last week (0202-0206)?
Weekly Report · 1d ago
Defence Therapeutics to Spotlight Accum Platform at World ADC Europe 2026
TipRanks · 6d ago
Defence Therapeutics Showcases Accum Drug-Delivery Platform at World ADC Europe
Reuters · 6d ago
More
About DTCFF
Defence Therapeutics Inc. is a Canada-based clinical-stage biotechnology company. The Company is engaged in developing and engineering the antibody drug conjugates (ADC) products using its proprietary platform. Its principal business activity is the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The core of its therapeutics platform is the ACCUM technology, which enables precision delivery ADCs in their intact form to target cells. The Company is focused on research, development and advancement of the main products using its Accum technology, which include ADC targeting various cancers, Anti-cancer AccuTOX program, Mesenchymal stromal cell-based vaccine (ARM-X) targeting cancer, mRNA vaccination, Cervical cancer vaccine, and Radio-immunoconjugates (RIC) targeting various cancers.

Webull offers Defence Therapeutics Inc stock information, including OTCMQB: DTCFF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DTCFF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DTCFF stock methods without spending real money on the virtual paper trading platform.